Results 31 to 40 of about 51,562 (315)

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood Advances, 2020
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and
L. Völker, J. Kaufeld, Wolfgang A. Miesbach, Sebastian Brähler, M. Reinhardt, Lucas Kühne, A. Mühlfeld, A. Schreiber, J. Gaedeke, M. Tölle, W. Jabs, Fedai Özcan, S. Markau, M. Girndt, F. Bauer, T. Westhoff, H. Felten, M. Hausberg, M. Brand, J. Gerth, M. Bieringer, M. Bommer, S. Zschiedrich, J. Schneider, S. Elitok, A. Gawlik, A. Gäckler, A. Kribben, V. Schwenger, U. Schoenermarck, M. Roeder, J. Radermacher, J. Bramstedt, A. Morgner, R. Herbst, Ana Harth, S. Potthoff, C. von Auer, R. Wendt, H. Christ, P. Brinkkoetter, J. Menne   +41 more
semanticscholar   +1 more source

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine

eJHaem, 2021
Acquired thrombotic thrombocytopenic purpura is characterized by the microvascular aggregation of platelets and microangiopathic hemolytic anemia causing ischemia of multiple organs including the brain mainly and less likely the kidney and the heart. The
M. Al‐Ahmad, M. Al-Rasheed, Neveen A. Shalaby   +2 more
semanticscholar   +1 more source

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

New England Journal of Medicine, 2019
BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune‐mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis ...
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J. Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, Debjit Biswas, H. de Winter, R. Zeldin   +12 more
semanticscholar   +1 more source

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Balkan Medical Journal, 2018
Background: Thrombotic thrombocytopenic purpura is a potentially life-threatening condition. Although the introduction of therapeutic plasma exchange has reduced mortality rates from over 90% to 10%-20%, approximately 40% of patients relapse, and ...
Seniz Öngören, Ayşe Salihoğlu, Tuğçe Apaydın, Sevil Sadri, Ahmet Emre Eşkazan, Muhlis Cem Ar, Tuğrul Elverdi, Zafer Başlar, Yıldız Aydın, Teoman Soysal   +9 more
doaj   +1 more source

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura [PDF]

Nature, 2001
Gallia G. Levy, William C. Nichols, Eric C.‐Y. Lian, Tatiana Foroud, Jeanette N. McClintick, Beth McGee, Angela Yang, David Siemieniak, Kenneth R. Stark, Ralph A. Gruppo, Ravi Sarode, Susan B. Shurin, Visalam Chandrasekaran, Sally P. Stabler, Hernan Sabio, Eric E. Bouhassira, Jefferson D. Upshaw, David Ginsburg, Han‐Mou Tsai   +18 more
openalex   +2 more sources

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood, 2020
Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation
George Goshua, P. Sinha, J. Hendrickson, C. Tormey, Pavan K Bendapudi, A. Lee   +5 more
semanticscholar   +1 more source

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine

Journal of Thrombosis and Haemostasis, 2021
In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS‐CoV‐2) pandemic. Autoimmune phenomenon have been
H. Maayan, I. Kirgner, O. Gutwein, K. Herzog-Tzarfati, N. Rahimi-Levene, M. Koren-Michowitz, D. Blickstein   +6 more
semanticscholar   +1 more source

Thrombotic Thrombocytopenic Purpura in Dengue Fever

Acta Medica Indonesiana, 2021
Thrombotic thrombocytopenic purpura is a rare but life threatening medical condition. Early recognition and treatment of thrombotic thrombocytopenic purpura is important especially in patients who do not present with the classic pentad to reduce the high
Tze Yuan Tee, Rizna Abdul Cader
doaj  

Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. [PDF]

, 2009
The activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome.
Bõze, Tamás, Cervenak, László, Derzsy, Zoltán, Gombos, Tímea, Hársfalvi, Jolán, Makó, Veronika, Molvarec, Attila, Prohászka, Zoltán, Rigó, János, Udvardy, Miklós László   +9 more
core   +1 more source

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

Haematologica, 2016
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13.
Wenjing Cao, Huy P. Pham, Lance A. Williams, Jenny McDaniel, Rance C. Siniard, Robin G. Lorenz, Marisa B. Marques, X. Long Zheng   +7 more
doaj   +1 more source